Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic avenue for managing metabolic syndromes. These naturally occurring molecules are secreted by the gut in response to meal intake, stimulating insulin release and suppressing glucagon secretion. GLP-1 derivatives demonstrate promising therapeutic results in treating type